Literature DB >> 28989039

First-Line Osimertinib in Patients with Treatment-Naive Somatic or Germline EGFR T790M-Mutant Metastatic NSCLC.

Katerina Ancevski Hunter1, David M Friedland1, Liza C Villaruz1, Timothy F Burns2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28989039     DOI： 10.1016/j.jtho.2017.09.1963

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  6 in total

1.  Significant Benefits of Osimertinib Against Adenosquamous Carcinoma Harboring Germline T790M Mutation.

Authors:  Ran Huo; Jinghua Li; Xiaofang Li; Junping Shi; Kunjie Wang; Jin Jiao; Yanhong Shang
Journal:  Oncologist       Date:  2020-06-11       Impact factor: 5.837

2.  The emergence of various genetic alterations mediated the Osimertinib resistance of a patient harboring heterozygous germline EGFR T790M: a case report.

Authors:  Bin Liu; Jianwen Qin; Yan Yin; Liang Zhai; Guangxin Liu; Analyn Lizaso; Dongsheng Shi
Journal:  Ann Transl Med       Date:  2021-01

3.  Lung squamous cell carcinoma with rare epidermal growth factor receptor mutation G719X: a case report and literature review.

Authors:  Huanhuan Bi; Dunqiang Ren; Jieqiong Wu; Xiaoqian Ding; Caihong Guo; Satoru Miura; Zsolt Megyesfalvi; Surein Arulananda; Hongmei Wang
Journal:  Ann Transl Med       Date:  2021-12

4.  Hybrid Pharmacophore- and Structure-Based Virtual Screening Pipeline to Identify Novel EGFR Inhibitors That Suppress Non-Small Cell Lung Cancer Cell Growth.

Authors:  Chia-Wei Weng; Chi-Hsuan Wei; Jeng-Yuan Tsai; Yi-Hua Lai; Gee-Chen Chang; Jeremy J W Chen
Journal:  Int J Mol Sci       Date:  2022-03-23       Impact factor: 5.923

5.  First-line osimertinib treatment in a patient with lung adenocarcinoma with coexisting epidermal growth factor receptor G719S and de novo T790M mutations.

Authors:  Noriaki Ito; Takeshi Masuda; Ikuko Ooka; Takatsune Hosoya; Kakuhiro Yamaguchi; Shinjiro Sakamoto; Yasushi Horimasu; Taku Nakashima; Shintaro Miyamoto; Hiroshi Iwamoto; Kazunori Fujitaka; Hironobu Hamada; Noboru Hattori
Journal:  Thorac Cancer       Date:  2022-01-25       Impact factor: 3.500

Review 6.  Advances in targeting acquired resistance mechanisms to epidermal growth factor receptor tyrosine kinase inhibitors.

Authors:  Justin A Chen; Jonathan W Riess
Journal:  J Thorac Dis       Date:  2020-05       Impact factor: 3.005
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.